• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

You thought VRX buying you was the worst thing, now look....









"Actavis Chief Executive Officer Brent Saunders said there are overlaps in corporate functions, including human relations and finance, though he hasn’t yet quantified how many positions will be eliminated."

No mention of sales and R&D.

In Bausch + Lomb Brent called it Spans and Layers. The deal is - less layers and more people working for each "level" manager. Throw in a little "stretch" factor to remove people and force their colleagues to work harder...you get the picture